202 related articles for article (PubMed ID: 18797463)
1. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
Le Tourneau C; Faivre S; Serova M; Raymond E
Br J Cancer; 2008 Oct; 99(8):1197-203. PubMed ID: 18797463
[TBL] [Abstract][Full Text] [Related]
2. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
3. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
4. Cellular and molecular effects of the mTOR inhibitor everolimus.
Saran U; Foti M; Dufour JF
Clin Sci (Lond); 2015 Nov; 129(10):895-914. PubMed ID: 26330617
[TBL] [Abstract][Full Text] [Related]
5. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
Gerullis H; Ecke TH; Eimer C; Heuck CJ; Otto T
Minerva Urol Nefrol; 2010 Dec; 62(4):411-23. PubMed ID: 20944541
[TBL] [Abstract][Full Text] [Related]
6. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
7. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
Armstrong AJ; George DJ; Halabi S
J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
[TBL] [Abstract][Full Text] [Related]
8. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.
Figlin RA; Kaufmann I; Brechbiel J
Int J Cancer; 2013 Aug; 133(4):788-96. PubMed ID: 23319457
[TBL] [Abstract][Full Text] [Related]
9. Role of mTOR Inhibitors in Kidney Disease.
Kajiwara M; Masuda S
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338360
[TBL] [Abstract][Full Text] [Related]
10. [mTOR inhibitors].
Oya M
Nihon Rinsho; 2010 Jun; 68(6):1067-71. PubMed ID: 20535957
[TBL] [Abstract][Full Text] [Related]
11. Temsirolimus for advanced renal cell carcinoma.
Bergmann L; Maute L; Guschmann M
Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
[TBL] [Abstract][Full Text] [Related]
12. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
13. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
14. mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option.
Dasanu CA; Clark BA; Alexandrescu DT
Expert Opin Investig Drugs; 2009 Feb; 18(2):175-87. PubMed ID: 19236264
[TBL] [Abstract][Full Text] [Related]
15. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
Huelsmann L; Kim DNW; Hannan R; Watumull LM; Brugarolas J
Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
[No Abstract] [Full Text] [Related]
16. Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.
Sakamoto H; Yamasaki T; Sumiyoshi T; Takeda M; Shibasaki N; Utsunomiya N; Arakaki R; Akamatsu S; Kobayashi T; Inoue T; Kamba T; Nakamura E; Ogawa O
Cancer Med; 2021 Jan; 10(1):119-134. PubMed ID: 33107222
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
18. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
19. [PI3K-AKT-mTOR pathway and cancer].
Coutte L; Dreyer C; Sablin MP; Faivre S; Raymond E
Bull Cancer; 2012 Feb; 99(2):173-80. PubMed ID: 21742593
[TBL] [Abstract][Full Text] [Related]
20. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
